EGFR and glioma: According to the latest classification, the prognosis and treatment of gliomas vary significantly depending on the glioma type—such as astrocytoma, IDH‐mutant (grades 2, 3, or 4), oligodendroglioma, IDH‐mutant with 1p/19q codeletion (grades 2 or 3), and glioblastoma, IDH‐wildtype (grade 4)—as well as on molecular markers including IDH1/2, H3‐3A, ATRX, CDKN2A/B, 1p/19q codeletion, TERT promoter mutations, MGMT promoter methylation, EGFR amplifications, PTEN deletions, and BRAF alterations [10, 11].